This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. More information about cookies is available in our privacy policy

The mission to
TRANSFORM MYELOMA

See how improved understanding of myeloma disease biology, insights into critical patient characteristics, and optimised treatment approaches are helping to turn the tables on a relentless disease.

The importance of achieving MRD negativity for impacting outcomes.

SEE THE IMPACT

Rethinking frailty and fitness when choosing a treatment for your elderly patients.

SEE THE LATEST RESEARCH

How patient factors can inform optimal treatment selection.

REVIEW THE CRITICAL FACTORS

Sanofi is dedicated to discovering and advancing new therapies in difficult-to-treat diseases like multiple myeloma. Our greatest commitment is to the patients we serve around the globe, and our goal is to provide healthcare providers with the tools to transform outcomes for their patients.

MRD=minimal residual disease.

211125_SANOFI_LOGO_RGB Copy
Myeloma FactsContactSite MapLegal NoticePrivacy & Data ProtectionCookies Policy

©2023 Sanofi-aventis Groupe. All rights reserved. Sanofi is a registered trademark of Sanofi or an affiliate.

MAT-GLB-2200930(V3.0) 10/23
MAT.US.2203027-v2.0-10/2023